GSK Strikes $2.5 Billion Deal with ABL Bio to Overcome Blood-Brain Barrier in Neurodegenerative Disease Therapies

Apr 08, 2025 06:00 CST Updated 06:00

GSK

Pharmaceutical R&D Manufacturer

ABL Bio

Developer of Immunooncology and Neurodegenerative Disease Therapeutics

Against the backdrop of accelerating global aging and a rising number of patients with neurodegenerative diseases, pharmaceutical giant GSK has recently made a significant move in the neuroscience field by entering into a collaboration agreement worth up to $2.5 billion with South Korean biotechnology company ABL Bio. The aim is to leverage its technology to break through the blood-brain barrier and develop innovative therapies for treating neurodegenerative diseases. This move not only highlights GSK's strategic layout in the neuroscience field but also brings new hope for overcoming neurodegenerative diseases.

Heavy Investment Layout, Focusing on the Field of Neurodegenerative Diseases

On April 7, 2025, GSK and ABL Bio officially announced a collaboration. Under the agreement, GSK will pay ABL Bio an upfront payment of £38.5 million (approximately $49.5 million), along with nearly $50 million in short-term payments. If long-term R&D, commercialization payments, and project expansion options are considered, the total deal value could reach up to £2.07 billion (approximately $2.5 billion). At the heart of this massive transaction is ABL Bio's proprietary Grabody-B platform technology.

ABL Bio's Grabody-B Platform Utilizes a Unique Targeting Mechanism by Binding Bispecific Antibodies to Insulin-like Growth Factor 1 Receptor (IGF1R) on Blood-brain Barrier Cells, Enabling Larger Therapeutic Molecules to Cross the Blood-brain Barrier and Enter the Brain. This Technology Offers New Possibilities for Treating Neurodegenerative Diseases, as Many Promising Novel Therapies, Such as Antibody Drugs, Are Hindered by the Blood-brain Barrier from Effectively Reaching the Brain.

Technology Empowers, Breaking Through the Blood-Brain Barrier Dilemma

The blood-brain barrier is an important defense mechanism of the human body. While it protects the brain from harmful substances, it also becomes an obstacle for many drugs trying to reach the brain. Neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease, often require drugs to directly target the brain to be effective. However, due to the presence of the blood-brain barrier, numerous potentially effective drugs have failed in clinical trials.

The emergence of the Grabody-B platform offers a new approach to solving this challenge. Through ingenious design, the platform enables therapeutic molecules to "ride" on the "coattails" of bispecific antibodies, successfully crossing the blood-brain barrier. ABL Bio has previously leveraged this technology in collaborations with Sanofi and I-Mab Biopharma, advancing research on bispecific antibodies for Parkinson’s disease and gastric cancer, respectively, thereby accumulating valuable experience and achieving significant results. This collaboration with GSK is expected to elevate the application of this technology in the field of neurodegenerative disease treatment to new heights.

Strategic Expansion, Deepening Layout in the Field of Neuroscience

In recent years, GSK has been actively expanding its presence in the field of neuroscience. In December 2024, GSK paid $35 million upfront to partner with Danish biotech company Muna Therapeutics, utilizing its MiND-MAP platform to identify new drug targets for Alzheimer's disease. In November of the same year, GSK also entered into a collaboration with Vesalius Therapeutics, paying an $80 million upfront fee to leverage its platform that integrates genomics, stem cells, and artificial intelligence for developing therapies targeting Parkinson’s disease and other neurodegenerative conditions.

This collaboration with ABL Bio marks another significant strategic move by GSK in the field of neuroscience. Christopher Austin, Senior Vice President of R&D Technology at GSK, stated that with the aging population, the prevalence of neurodegenerative brain diseases is rising rapidly, creating an urgent need for new therapies. ABL Bio’s technology provides GSK with an innovative platform to help overcome the blood-brain barrier, paving new ways to treat these devastating diseases and forming an essential part of GSK's emerging R&D pipeline.

ABL Bio CEO Sang Hoon Lee also stated that the collaboration with GSK will solidify ABL Bio's position in the neurodegenerative disease treatment market through the potential commercialization of the Grabody-B platform, while expanding the application scope of the platform. It is hoped that this collaboration will accelerate the development of innovative therapies and bring new hope to patients worldwide.

Prospects and Contributions to Tackling Neurological Disease Challenges

Currently, the number of patients with neurodegenerative diseases worldwide is large and on the rise, but effective treatment options remain relatively limited. The collaboration between GSK and ABL Bio undoubtedly injects new vitality into this field. Leveraging ABL Bio's technology, GSK is expected to develop a series of innovative therapies targeting neurodegenerative diseases, improving patients' quality of life and potentially altering the course of these conditions.

However, there are still many challenges from technology to clinical application, such as drug safety, efficacy verification, the advancement of clinical trials, and the realization of commercialization, among others. Nevertheless, this collaboration has brought new hope to the field of neuroscience. In the future, as research and development deepen, we look forward to seeing more outcomes based on this partnership emerge, bringing tangible help to patients with neurodegenerative diseases worldwide.

Reference Source;

https://www.fiercebiotech.com/biotech/gsks-pens-25b-pact-use-abl-bios-tech-bypass-blood-brain-barrierhttps://www.biospace.com/business/gsk-dives-deeper-into-neuro-with-2-5b-abl-bio-pact

Scan the WeChat QR code, add the editor of the Biologics Circle, and those who meet the requirements can join.

Biological Products WeChat Group!

Please indicate: Name + Research Direction!

Edition

Authority

Sound

Bright

All reproduced articles in this official account are intended to convey more information, with clear attribution of sources and authors. Media or individuals who do not wish to be reproduced can contact us (cbplib@163.com), and we will immediately proceed with deletion. All articles represent the views of the authors and not of this site.